




**Predictive
Oncology®**

www.predictive-oncology.com

Pennsylvania
(Headquarters)
91 43rd Street
Suite 110
Pittsburgh, PA 15201
(412) 432-1500

Alabama
200 Riverhills Business Park,
Suite 250
Birmingham, AL 35242
(205) 922-5400

Minnesota
2915 Commers Drive
Suite 900
Eagan, MN 55121
(651) 389-4800



Christoph Reinhard, Ph.D., MBA

Member

Christoph Reinhard, Ph.D., MBA, is a leader in oncology translational research, new technologies in drug development and external innovation.

He currently serves as acting Chief Scientific Officer for CELLphenomics, where he is instrumental in determining what types of novel drugs and drug combinations might be beneficial to future cancer patients with solid tumors.

For more than a decade Dr. Reinhard worked at Eli Lilly (NYSE:LLY) where he was responsible for strategy development and implementation of translational research support for its oncology portfolio assets and spearheaded the company's Innovative Medicine Initiative in Oncology.

Dr. Reinhard holds a Ph.D. from the Biocenter University, Basel, Switzerland; an MBA in Technology Management from Phoenix University; and a Bachelor of Science in Molecular Biology, Biochemistry and Microbiology from the University of Freiburg in Germany.